HP NSC Announcement

What this means for practice?

There are no immediate changes to clinical practice. The UK NSC has recommended targeted screening for men aged 45 to 61 with a BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer. In the meantime, it remains important to support men at higher risk, including Black men, who face double the risk of prostate cancer, men with a family history and men with BRCA gene variations, to understand their risk and make informed decisions about PSA testing.

Use the form below to share any feedback, questions, or concerns regarding the NSC screening recommendation to help us understand how best to support you.

Share your voice

LATEST UPDATE

On 2 June 2026, the government announced an additional £18 million from the Department of Health and Social Care to expand the TRANSFORM trial. This will increase the scope of phase 2 of the study, so that all Black men aged between 45 to 74 who haven’t had a recent PSA test will now be invited to participate. This major expansion will speed up and strengthen the evidence base for screening men at higher risk more widely.

The extra investment increases this once-in-a-generation study to a £60 million trial, making it the largest prostate cancer screening trial in two decades and the most diverse and representative of the UK population ever undertaken.

It's a significant moment for men’s health and moves us closer to a national screening programme for all men at risk of prostate cancer.

Professor Hashim Ahmed, Chief Investigator of the TRANSFORM trial, said: "It is a truly game changing investment in the future of men’s health and a clear indication in the Government’s support for and belief in our trial to achieve its aims."

Laura Kerby, our Chief Executive, commented: "After so much disappointment, this announcement is a truly historic moment, bringing us a step closer to a world where no man dies from prostate cancer.”

This announcement follows the UK NSC publishing its final recommendation on 28 May 2026 in favour of a targeted screening programme for men aged 45 to 61 with a BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer.

The committee said there was not yet enough evidence to recommend targeted screening for other risk groups and that continued research, including through TRANSFORM, will help address these evidence gaps for Black men and other groups at higher risk.

The UK NSC is hopeful that new and further evidence, improved tests and a better understanding of prostate cancer may support wider screening in future.

Over the next few years, the TRANSFORM trial will provide evidence to inform future NSC recommendations and help determine whether screening can be expanded safely and effectively to additional groups of men at risk.

As a GP I’ve had far too many conversations with men who didn’t know they were at risk of prostate cancer, who didn’t know how to get a blood test to check for early warning signs, who didn’t know an early diagnosis could save their life. My hope is that, for men in the future, it’s a very different story. Where men are not only made aware when they’re at risk, but that an effective nationwide screening programme makes sure they’re invited for routine tests in time to make a real difference.

Dr Bunmi Olajide GP, Member of our Clinical Advisory Group and Black Men's Health Advisory Group

Additional information

Read our news and views piece about the additional £18 million from the government to boost our groundbreaking TRANSFORM trial.
Learn more about our TRANSFORM trial
View our response to May's 2025 prostate cancer screening recommendations from the UK National Screening Committee.
Read our statement below, co-signed by the British Association of Urological Surgeons (BAUS), Royal College of Physicians and Surgeons of Glasgow, the British Association of Urological Nurses (BAUN) and other key stakeholders.

Stay informed

Check this page regularly for updates.
Visit our FAQs page on the NSC recommendation.

Sign up to our monthly e-newsletter for health professionals to receive the latest news, opportunities, education and clinical resources for you and your patients.